Gerber Kawasaki Wealth & Investment Management Intellia Therapeutics, Inc. Transaction History

Gerber Kawasaki Wealth & Investment Management

$2.28 Billion
Q4 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$38.49 - $76.21 $137,409 - $272,069	-3,570 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$100.76 - $138.36 $10,076 - $13,836	-100 Reduced 2.72%	3,570 $422,000
Q1 2021 May 07, 2021	BUY	$46.59 - $83.68 $170,985 - $307,105	3,670 New	3,670 $294,000

Others Institutions Holding NTLA

# of Institutions

336

Shares Held

96.1M

Call Options Held

1.06M

Put Options Held

863K

Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

12.5M
Shares

$119 Million
1.28% of portfolio
Vanguard Group Inc Valley Forge, PA

10.2M
Shares

$96.4 Million
0.0% of portfolio
Black Rock Inc. New York, NY

9.6M
Shares

$90.8 Million
0.0% of portfolio
State Street Corp Boston, MA

5.21M
Shares

$49.2 Million
0.0% of portfolio
Morgan Stanley New York, NY

3.81M
Shares

$36.1 Million
0.0% of portfolio

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $719M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gerber Kawasaki Wealth & Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Gerber Kawasaki Wealth & Investment Management with notifications on news.

Account